Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

News

Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

09 Mar, 2010

Published over 16 years ago. See the latest and most current information on News.

Gyros® AB, a leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, a leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries. Gyrolab has rapidly become established as a preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organisations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Walldén, CEO and President of Gyros. “It’s an organisation with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. S. E. Kim, CEO and President at DI Biotech comments: “We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognised in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government’s recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the ‘SMART project’, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”

Latest News

ILM 51.6 Sept 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Connected safety technology company announces CEO appointment and leadership transition
Explore more Arrow
Pollution Solutions Online
Smarter wastewater management helps futureproof distillery operations and protect local watercourses
Explore more Arrow
Petro Online
Sustainable fuel lubricity testing in focus at Gulf Coast Conference 2026
Explore more Arrow
Chromatography Today
Dr. Anupam Giri joins Chromatography Today as consultant editor to strengthen its technical expertise
Explore more Arrow